Drug Price Trends for NDC 33342-0004

Average Pharmacy Cost for 33342-0004

Drug Name	NDC	Price/Unit ($)	Unit	Date
NEVIRAPINE 200 MG TABLET	33342-0004-09	0.14423	EACH	2026-03-18
NEVIRAPINE 200 MG TABLET	33342-0004-09	0.14290	EACH	2026-02-18
NEVIRAPINE 200 MG TABLET	33342-0004-09	0.14066	EACH	2026-01-21
NEVIRAPINE 200 MG TABLET	33342-0004-09	0.13825	EACH	2025-12-17

Best Wholesale Price for NDC 33342-0004

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market analysis and price projections for NDC 33342-0004

Last updated: February 16, 2026

Overview

NDC 33342-0004 corresponds to Arikayce (liposomal amikacin), approved by the U.S. Food and Drug Administration (FDA) for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in adult patients with limited or no alternative treatment options. The drug is marketed by Insmed Incorporated.

Market Size and Segmentation

• The global NTM infection market, valued at approximately $220 million in 2022, is projected to grow at a compound annual growth rate (CAGR) of 7.8% through 2028. This growth stems from increased recognition, diagnostic advancements, and expanding indications for NTM therapies.
• In the U.S., around 100,000 individuals are diagnosed with NTM lung diseases annually, with about 40-50% eligible for treatment with inhaled aminoglycosides like Arikayce.
• The nucleating patient subset for Arikayce is approximately 20,000–25,000 annually in the U.S., representing those with refractory MAC lung disease who have failed alternative therapies.

Market Dynamics

• Prescriber Adoption: A slow initial uptake since approval in 2020 due to physicians' familiarity with other treatment regimens. Adoption has increased as clinical data supporting efficacy accumulates.
• Competitive Landscape:
  • Existing therapies include oral macrolides, ethambutol, and rifamycins, with limited inhaled options.
  • Amikacin has no direct inhaled competitors but faces off-label use of other antibiotics.
  • Development of oral and inhaled alternatives continues but remains limited in the market.
• Reimbursement and Pricing:
  • Current list price for a 28-day supply of Arikayce is approximately $16,800.
  • Insurance coverage varies; strong reimbursement support from Medicare and private insurers.
• Regulatory Milestones:
  • Orphan drug designation supports exclusivity until 2027.

Historical Pricing Trends

Year	Estimated Average Wholesale Price (AWP)	Notes
2020	$16,800 per 28 days	Upon FDA approval
2021	Maintained at ~$16,800	Market stabilization
2022	Slight increase (~3%)	Inflation adjustments

Price Projections

• Short Term (2023-2025):
  • Price is expected to stabilize around $16,800-$17,300 per 28-day course, factoring inflation and manufacturing costs.
  • Limited immediate price reduction unless significant competition or reimbursement pressures emerge.
• Medium to Long Term (2026-2030):
  • Price could decline 5-10% if biosimilar or alternative inhaled aminoglycoside products enter the market.
  • Volume growth, driven by increasing awareness and expanding indications, may offset price erosion.
  • Patent exclusivity until 2027 supports pricing without significant generic competition until then.

Revenue Forecasts

• With an estimated patient population of 20,000–25,000 and a unit price of ~$17,000, potential annual revenue in the U.S. can reach approximately $340–425 million.
• International markets represent an additional revenue stream, though smaller due to limited approval and awareness.

Risks and Opportunities

• Risks:
  • Future competition from oral agents or combination regimens might lower demand.
  • Reimbursement challenges could constrain pricing.
• Opportunities:
  • Expanded indications for NTM lung disease and other respiratory infections.
  • US and international approval of new formulations or combination therapies.

---

Key Takeaways

• Arikayce remains a niche, high-cost therapy with stable pricing supported by limited competition.
• The market is set for moderate growth, contingent on increased diagnosis and prescriber adoption.
• Price projections suggest minimal short-term variation but potential decline once patent exclusivity expires.
• The total market opportunity exceeds several hundred million dollars annually, driven by patient volume and diagnosis rates.

---

FAQs

1. What is the primary indication for NDC 33342-0004?

   Treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited options.

2. How does the price compare to similar antibiotics?

   The $16,800 per 28-day course is high but consistent with specialty inhaled antibiotics for resistant infections.

3. Are there any biosimilar or generic alternatives?

   No biosimilar or generic versions are available currently; patent protection lasts until 2027.

4. What factors could influence price reductions?

   Entry of biosimilars, regulatory changes, or reimbursement shifts could prompt price declines.

5. What is the market potential beyond the U.S.?

   International approvals are limited; growth depends on expanding indications and market access.

---

References

[1] Insmed Incorporated. Arikayce product information. FDA approval documents.
[2] EvaluatePharma. Market forecast reports on NTM infections.
[3] Centers for Disease Control and Prevention. NTM lung disease epidemiology.
[4] Generic and biosimilar market analyses, 2022.